Received Jan 23, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | UNK | — | — |
The cancer was back with a vengeance; tumor had metastasized to his liver; This is a literature report from License Party for the following literature source(s). Other Case identifier(s): AE-022259 (BionNTech SE). A male patient received BNT162b2 (BNT162B2), in 2022 as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "HPV-reIated head and neck cancer", start date: 2015 (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: RECURRENT CANCER (medically significant), outcome "unknown", described as "The cancer was back with a vengeance"; METASTASES TO LIVER (medically significant), outcome "unknown", described as "tumor had metastasized to his liver". Clinical Course: Human Papilloma Virus (HPV) is a causative agent in several cancers including cervical cancer, head and neck cancer, anal cancer, penile, vulvar and vaginal cancers. HPV through its virus-encoded protein E6 and the cellular E6-Associated protein (E64P) target the tumor suppressor p53 protein for degradation thereby contributing to cancer development after HPV infection, as viruses cause cancer, the author previously hypothesized that SARS-COV-2 virus may be associated with cancer. More recent insights on the present hypothesis have come trom studies suggesting Spike protein or SARS-COV-2 may suppress p53 function, cancer has been associated with mRNA vaccines that produce Spike, and a case mentioned by Dr. (Withheld) of a patient who survived HPV-associated head and neck cancer, but the tumor recurred after COVID mRNA vaccination including with liver metastases. Thus, the present hypothesis is that virally encoded proteins such as HPV-E6 or SARS-COV-2 Spike may cooperate in suppressing host defenses including tumor suppressor mechanisms involving p53. The hypothesis can be further explored through epidemiologic and laboratory studies. I listened to an interview withheld of Dr. Name withheld by withheld where I learned about a patient named name withheld with a history of HPV-related head and neck cancer who by 2022 had survived his HPV-related cancer for 7 years and then he took the COVID vaccine. The cancer was back with a vengeance,' and the tumor had metastasized to his liver. After I listened to what happened in this case, it occurred to me that there may be cooperation between HPV and COVID infection or COVID vaccination and suppression of p53. A search of the literature for "cooperation between HPV and COVID in suppressing p53" found per an Al overview that there is "no evidence of a direct molecular "cooperation" between HPV and COVID-19 in suppressing p53, research indicates they both target the p53 pathway independently, and a COVID-19 infection may indirectly accelerate HPV-related cancer progression by impacting the host immune system." I found a publication about SARS-CoV-2 infection heightening the risk of developing HPV-reIated carcinoma in situ and cancer and a hypothesis that "COVID-19 can lead to rapid progression of cervical intraepithelial neoplasia by dysregulating the immune system." No follow-up attempts are possible. SUSPECT PRODUCT is under agreement with BIONTECH SE.; Sender's Comments: The reported events Recurrent cancer and metastases to liver are likely due to the natural course of the underlying malignancy and not related to suspect product use. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate.
Medical History/Concurrent Conditions: Head and neck cancer